Tag: exchange

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the...

BEIJING, June 11, 2026 /PRNewswire/ -- A report from People's Daily: The second World Conference of Classics convened on June 9 and 10 in Athens,...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

CALGARY, AB, June 10, 2026 /PRNewswire/ - Horizon Petroleum Ltd. ("Horizon" or the "Company") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to announce the...

CALGARY AB, June 10, 2026 /CNW/ - InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) ("InPlay" or the "Company") announced today the voting results for the election of directors at its...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Toobit unveils Prediction Market, allowing traders to hedge risk and profit from crypto, financial, and global event forecasts using USDT.

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

VANCOUVER, BC, June 11, 2026 /PRNewswire/ -- (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce...

VANCOUVER, BC, June 10, 2026 /CNW/ - (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce the...